331. 特発性多中心性キャッスルマン病 Disease details / Clinical trials / Drug dev / DR info

Bevacizumab
   M.D. Anderson Cancer Center
      2012   Phase 1   NCT01552434   United States
Bortezomib
   National Cancer Institute (NCI)
      2004   Phase 2   NCT00092222   United States
   Peking Union Medical College Hospital
      2019   Phase 2   NCT03982771   China
Cetuximab
   M.D. Anderson Cancer Center
      2012   Phase 1   NCT01552434   United States
Chimeric murine human ANTI-IL-6 monoclonal antibody
   Centocor BV
      2010   Phase 2   EUCTR2009-012380-34-FR   Belgium;France;Germany;Hungary;Netherlands;Spain;United Kingdom
      2009   Phase 2   EUCTR2009-012380-34-ES   Belgium;France;Germany;Hungary;Netherlands;Spain;United Kingdom
   Janssen Biologics B.V.
      2010   Phase 2   EUCTR2009-012380-34-NL   Belgium;France;Germany;Hungary;Netherlands;Spain;United Kingdom
   Janssen Biologics BV
      2010   -   EUCTR2009-012380-34-HU   Belgium;France;Germany;Hungary;Netherlands;Spain;United Kingdom
   Janssen-Cilag International N.V.
      2010   -   EUCTR2009-012380-34-DE   Belgium;France;Germany;Hungary;Netherlands;Spain;United Kingdom
   Janssen-Cilag International N.V.
      2010   Phase 2   EUCTR2009-012380-34-GB   Australia;Belgium;Brazil;Canada;China;Egypt;France;Germany;Hong Kong;Hungary;India;Israel;Korea, Republic of;Malaysia;Netherlands;New Zealand;Norway;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States
      2010   Phase 2   EUCTR2009-012380-34-BE   Australia;Belgium;Brazil;Canada;China;Egypt;France;Germany;Hong Kong;Hungary;India;Israel;Korea, Republic of;Malaysia;Netherlands;New Zealand;Norway;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States
Cnto 328
   Centocor BV
      2010   Phase 2   EUCTR2009-012380-34-FR   Belgium;France;Germany;Hungary;Netherlands;Spain;United Kingdom
      2009   Phase 2   EUCTR2009-012380-34-ES   Belgium;France;Germany;Hungary;Netherlands;Spain;United Kingdom
   Centocor, Inc.
      2005   Phase 1   NCT00412321   United States
   Janssen Biologics B.V.
      2010   Phase 2   EUCTR2009-012380-34-NL   Belgium;France;Germany;Hungary;Netherlands;Spain;United Kingdom
   Janssen Biologics BV
      2010   -   EUCTR2009-012380-34-HU   Belgium;France;Germany;Hungary;Netherlands;Spain;United Kingdom
   Janssen-Cilag International N.V.
      2010   -   EUCTR2009-012380-34-DE   Belgium;France;Germany;Hungary;Netherlands;Spain;United Kingdom
   Janssen-Cilag International N.V.
      2010   Phase 2   EUCTR2009-012380-34-GB   Australia;Belgium;Brazil;Canada;China;Egypt;France;Germany;Hong Kong;Hungary;India;Israel;Korea, Republic of;Malaysia;Netherlands;New Zealand;Norway;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States
      2010   Phase 2   EUCTR2009-012380-34-BE   Australia;Belgium;Brazil;Canada;China;Egypt;France;Germany;Hong Kong;Hungary;India;Israel;Korea, Republic of;Malaysia;Netherlands;New Zealand;Norway;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States
CNTO328
   Centocor BV
      2010   Phase 2   EUCTR2009-012380-34-FR   Belgium;France;Germany;Hungary;Netherlands;Spain;United Kingdom
      2009   Phase 2   EUCTR2009-012380-34-ES   Belgium;France;Germany;Hungary;Netherlands;Spain;United Kingdom
   Janssen Biologics B.V.
      2010   Phase 2   EUCTR2009-012380-34-NL   Belgium;France;Germany;Hungary;Netherlands;Spain;United Kingdom
   Janssen Biologics BV
      2010   -   EUCTR2009-012380-34-HU   Belgium;France;Germany;Hungary;Netherlands;Spain;United Kingdom
   Janssen-Cilag International N.V.
      2010   -   EUCTR2009-012380-34-DE   Belgium;France;Germany;Hungary;Netherlands;Spain;United Kingdom
   Janssen-Cilag International N.V.
      2013   Phase 2   EUCTR2010-022837-27-GB   Belgium;Brazil;Canada;China;Egypt;France;Germany;Hong Kong;Israel;Korea, Republic of;New Zealand;Norway;Singapore;Spain;Taiwan;United Kingdom;United States
      2012   Phase 2   EUCTR2010-022837-27-ES   Belgium;Brazil;Canada;China;Egypt;France;Germany;Hong Kong;Israel;Korea, Republic of;New Zealand;Norway;Singapore;Spain;Taiwan;United Kingdom;United States
      2012   Phase 2   EUCTR2010-022837-27-DE   Belgium;Brazil;Canada;China;Egypt;France;Germany;Hong Kong;Israel;Korea, Republic of;New Zealand;Norway;Singapore;Spain;Taiwan;United Kingdom;United States
      2012   Phase 2   EUCTR2010-022837-27-BE   Belgium;Brazil;Canada;China;Egypt;France;Germany;Hong Kong;Israel;Korea, Republic of;New Zealand;Norway;Singapore;Spain;Taiwan;United Kingdom;United States
      2010   Phase 2   EUCTR2009-012380-34-GB   Australia;Belgium;Brazil;Canada;China;Egypt;France;Germany;Hong Kong;Hungary;India;Israel;Korea, Republic of;Malaysia;Netherlands;New Zealand;Norway;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States
      2010   Phase 2   EUCTR2009-012380-34-BE   Australia;Belgium;Brazil;Canada;China;Egypt;France;Germany;Hong Kong;Hungary;India;Israel;Korea, Republic of;Malaysia;Netherlands;New Zealand;Norway;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States
CX-4945 oral formulation
   Cylene Pharmaceuticals
      2009   Phase 1   NCT00891280   United States
Cyclophosphamide
   Fred Hutchinson Cancer Center
      2019   Phase 1   NCT03864419   Uganda;United States
   National Cancer Institute (NCI)
      2014   Phase 1/Phase 2   NCT02228512   United States
      2004   Phase 2   NCT00092222   United States
   Peking Union Medical College Hospital
      2019   Phase 2   NCT03982771   China
   The first affiliated hospital of Zhejiang University
      2023   Phase 0   ChiCTR2300077200   China
Daratumumab SC
   National Cancer Institute (NCI)
      2024   Phase 2   NCT05907759   United States
Dexamethason
   Peking Union Medical College Hospital
      2019   Phase 2   NCT03982771   China
Dexamethasone
   The first affiliated hospital of Zhejiang University
      2023   Phase 0   ChiCTR2300077200   China
Doxorubicin
   National Cancer Institute (NCI)
      2014   Phase 1/Phase 2   NCT02228512   United States
Doxorubicin hydrochloride
   Fred Hutchinson Cancer Center
      2019   Phase 1   NCT03864419   Uganda;United States
Etoposide
   Fred Hutchinson Cancer Center
      2019   Phase 1   NCT03864419   Uganda;United States
   National Cancer Institute (NCI)
      2014   Phase 1/Phase 2   NCT02228512   United States
      2004   Phase 2   NCT00092222   United States
   UNC Lineberger Comprehensive Cancer Center
      2021   Phase 2   NCT04585893   Malawi
Filgotinib
   Kawakami Atsushi
      2024   Phase 1-2   JPRN-jRCTs071230120   -
      2024   Phase 1   JPRN-jRCT2071230108   -
Filgrastim
   National Cancer Institute (NCI)
      2004   Phase 2   NCT00092222   United States
G-CSF
   National Cancer Institute (NCI)
      2004   Phase 2   NCT00092222   United States
Interferon-alpha
   National Cancer Institute (NCI)
      2004   Phase 2   NCT00092222   United States
Laboratory biomarker analysis
   M.D. Anderson Cancer Center
      2012   Phase 1   NCT01552434   United States
Lenalidomide
   Department of Hematology, Jiangsu Provincial People's Hospital
      2021   Phase 4   ChiCTR2100048364   China
Liposomal doxorubicin
   National Cancer Institute (NCI)
      2004   Phase 2   NCT00092222   United States
Methotrexate
   Fred Hutchinson Cancer Center
      2019   Phase 1   NCT03864419   Uganda;United States
Nelfinavir
   Sidney Kimmel Comprehensive Cancer Center
      2014   Phase 0   NCT02080416   United States
Nintedanib
   Assistance Publique - Hôpitaux de Paris
      2024   Phase 2   NCT06643091   -
Observation only
   National Cancer Institute (NCI)
      2004   Phase 2   NCT00092222   United States
Pacritinib
   National Cancer Institute (NCI)
      2025   Phase 2   NCT06052618   United States
Pharmacological study
   M.D. Anderson Cancer Center
      2012   Phase 1   NCT01552434   United States
Pomalidomide
   National Cancer Institute (NCI)
      2014   Phase 1/Phase 2   NCT02228512   United States
Prednisone
   Fred Hutchinson Cancer Center
      2019   Phase 1   NCT03864419   Uganda;United States
   National Cancer Institute (NCI)
      2014   Phase 1/Phase 2   NCT02228512   United States
      2004   Phase 2   NCT00092222   United States
Recombinant humanized ANTI-interleukin-6 receptor monoclonal antibody injection 4MG/KG
   Beijing VDJBio Co., LTD.
      2022   Phase 2   NCT05345522   China
Recombinant humanized ANTI-interleukin-6 receptor monoclonal antibody injection 6MG/KG
   Beijing VDJBio Co., LTD.
      2022   Phase 2   NCT05345522   China
Recombinant humanized ANTI-interleukin-6 receptor monoclonal antibody injection 8MG/KG
   Beijing VDJBio Co., LTD.
      2022   Phase 2   NCT05345522   China
Rituximab
   Department of Hematology, Jiangsu Provincial People's Hospital
      2021   Phase 4   ChiCTR2100048364   China
   French National Agency for Research on AIDS and Viral Hepatitis
      2003   Phase 2   NCT00127569   -
   National Cancer Institute (NCI)
      2014   Phase 1/Phase 2   NCT02228512   United States
      2004   Phase 2   NCT00092222   United States
   The first affiliated hospital of Zhejiang University
      2023   Phase 0   ChiCTR2300077200   China
   UNC Lineberger Comprehensive Cancer Center
      2021   Phase 2   NCT04585893   Malawi
Rituximab and hyaluronidase human
   Fred Hutchinson Cancer Center
      2019   Phase 1   NCT03864419   Uganda;United States
Siltuximab
   EusaPharma (UK) Limited
      2021   Phase 2   NCT04838860   United States
   Janssen Research & Development, LLC
      2011   Phase 2   NCT01400503   Belgium;Brazil;Canada;China;Egypt;France;Germany;Hong Kong;Israel;Korea, Republic of;New Zealand;Norway;Singapore;Spain;Taiwan;United Kingdom;United States
      2010   Phase 2   NCT01024036   Australia;Belgium;Brazil;Canada;China;Egypt;France;Germany;Hong Kong;Hungary;India;Israel;Jordan;Korea, Republic of;Malaysia;Netherlands;New Zealand;Norway;Poland;Russian Federation;Singapore;Spain;Taiwan;United Kingdom;United States
   Janssen-Cilag International N.V.
      2013   Phase 2   EUCTR2010-022837-27-GB   Belgium;Brazil;Canada;China;Egypt;France;Germany;Hong Kong;Israel;Korea, Republic of;New Zealand;Norway;Singapore;Spain;Taiwan;United Kingdom;United States
      2012   Phase 2   EUCTR2010-022837-27-ES   Belgium;Brazil;Canada;China;Egypt;France;Germany;Hong Kong;Israel;Korea, Republic of;New Zealand;Norway;Singapore;Spain;Taiwan;United Kingdom;United States
      2012   Phase 2   EUCTR2010-022837-27-DE   Belgium;Brazil;Canada;China;Egypt;France;Germany;Hong Kong;Israel;Korea, Republic of;New Zealand;Norway;Singapore;Spain;Taiwan;United Kingdom;United States
      2012   Phase 2   EUCTR2010-022837-27-BE   Belgium;Brazil;Canada;China;Egypt;France;Germany;Hong Kong;Israel;Korea, Republic of;New Zealand;Norway;Singapore;Spain;Taiwan;United Kingdom;United States
Sirolimus
   Kawakami Atsushi
      2020   Phase 2   JPRN-jRCT2071190029   -
   National Cancer Institute (NCI)
      2004   Phase 2   NCT00092222   United States
   University of Pennsylvania
      2019   Phase 2   NCT03933904   United States
Suramin
   University of Arkansas
      1995   Phase 2   NCT00002652   United States
Temsirolimus
   M.D. Anderson Cancer Center
      2012   Phase 1   NCT01552434   United States
Thalidomide, cyclophosphamide and prednisone
   Peking Union Medical College Hospital
      2017   Phase 2   NCT03043105   China
Tocilizumab
   Hoffmann-La Roche
      2006   Phase 1   NCT01183598   United States
   National Cancer Institute (NCI)
      2011   Phase 2   NCT01441063   United States
Valganciclovir
   National Cancer Institute (NCI)
      2011   Phase 2   NCT01441063   United States
      2004   Phase 2   NCT00092222   United States
   University of Washington
      2008   Phase 4   NCT00361933   United States
Valproic acid
   M.D. Anderson Cancer Center
      2012   Phase 1   NCT01552434   United States
Vincristine
   Fred Hutchinson Cancer Center
      2019   Phase 1   NCT03864419   Uganda;United States
   National Cancer Institute (NCI)
      2014   Phase 1/Phase 2   NCT02228512   United States
      2004   Phase 2   NCT00092222   United States
Zanubrutinib
   Peking Union Medical College Hospital
      2021   Phase 2   NCT04743687   China
Zidovudine
   National Cancer Institute (NCI)
      2011   Phase 2   NCT01441063   United States
      2004   Phase 2   NCT00092222   United States